Johnson & Johnson (NYSE:JNJ) Shares Sold by MinichMacGregor Wealth Management LLC

Posted by Defense World Staff on Sep 25th, 2023

MinichMacGregor Wealth Management LLC cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 6.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,805 shares of the company’s stock after selling 190 shares during the period. MinichMacGregor Wealth Management LLC’s holdings in Johnson & Johnson were worth $464,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Sawyer & Company Inc increased its stake in shares of Johnson & Johnson by 1.1% in the second quarter. Sawyer & Company Inc now owns 25,912 shares of the company’s stock worth $4,289,000 after acquiring an additional 270 shares during the period. Franklin Street Advisors Inc. NC grew its position in Johnson & Johnson by 0.7% during the 2nd quarter. Franklin Street Advisors Inc. NC now owns 80,179 shares of the company’s stock worth $13,271,000 after purchasing an additional 562 shares during the period. Marcum Wealth LLC raised its stake in shares of Johnson & Johnson by 0.5% during the 2nd quarter. Marcum Wealth LLC now owns 17,716 shares of the company’s stock valued at $2,932,000 after buying an additional 89 shares during the last quarter. Prairie Sky Financial Group LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $7,617,000. Finally, Wesbanco Bank Inc. grew its holdings in Johnson & Johnson by 0.4% during the second quarter. Wesbanco Bank Inc. now owns 262,724 shares of the company’s stock worth $43,486,000 after acquiring an additional 1,089 shares during the period. 68.40% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.7 %

Shares of JNJ opened at $160.50 on Monday. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04. The stock has a market cap of $417.13 billion, a PE ratio of 32.49, a price-to-earnings-growth ratio of 3.25 and a beta of 0.54. The firm’s fifty day moving average is $166.51 and its two-hundred day moving average is $162.06. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. Johnson & Johnson’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.59 EPS. Research analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were given a dividend of $1.19 per share. The ex-dividend date was Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.97%. Johnson & Johnson’s payout ratio is 96.36%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the business’s stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares in the company, valued at approximately $15,092,484. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of analyst reports. Atlantic Securities boosted their price target on Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a report on Friday, August 4th. JPMorgan Chase & Co. boosted their target price on shares of Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, September 18th. Barclays decreased their price objective on shares of Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating for the company in a research report on Friday, September 8th. Finally, StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 20th. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of “Hold” and a consensus price target of $170.65.

View Our Latest Report on Johnson & Johnson

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.